BIOMAT Database Logo BIOMAT Database Logo

Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. 1993

I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, Canada.

Basic fibroblast growth factor (bFGF) has a neurotrophic effect on mesencephalic dopaminergic neurons in vitro and in vivo. To explore whether an abnormality in bFGF expression occurs in Parkinson's disease (PD), we examined the substantia nigra (SN) of six PD and eight control cases immunohistochemically using a monoclonal antibody to bFGF. The mean number of melanin-positive neurons in sections of PD SN was 30.3% of the control mean, but the number of bFGF-immunopositive neurons was only 4.7% of the control mean. bFGF-immunoreactivity was present in only 8.2% of PD, but in 93.7% of control melanin-positive neurons. These results suggest a profound depletion of bFGF in surviving dopaminergic neurons of the SN in PD, and this depletion may be related to the disease process.

UI MeSH Term Description Entries
D007091 Image Processing, Computer-Assisted A technique of inputting two-dimensional or three-dimensional images into a computer and then enhancing or analyzing the imagery into a form that is more useful to the human observer. Biomedical Image Processing,Computer-Assisted Image Processing,Digital Image Processing,Image Analysis, Computer-Assisted,Image Reconstruction,Medical Image Processing,Analysis, Computer-Assisted Image,Computer-Assisted Image Analysis,Computer Assisted Image Analysis,Computer Assisted Image Processing,Computer-Assisted Image Analyses,Image Analyses, Computer-Assisted,Image Analysis, Computer Assisted,Image Processing, Biomedical,Image Processing, Computer Assisted,Image Processing, Digital,Image Processing, Medical,Image Processings, Medical,Image Reconstructions,Medical Image Processings,Processing, Biomedical Image,Processing, Digital Image,Processing, Medical Image,Processings, Digital Image,Processings, Medical Image,Reconstruction, Image,Reconstructions, Image
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Substantia nigra pars reticulata neurons in Parkinson's disease.
March 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Age-related changes in basic fibroblast growth factor-immunoreactive cells of rat substantia nigra.
August 1995, Mechanisms of ageing and development,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Directional induction of dopaminergic neurons from neural stem cells using substantia nigra homogenates and basic fibroblast growth factor.
March 2012, Neural regeneration research,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.
January 1994, Acta neuropathologica,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases.
June 1998, Brain research,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Substantia nigra hyperechogenicity in Parkinson's disease.
December 2010, Acta neurochirurgica,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Mean volume of pigmented neurons in the substantia nigra in Parkinson's disease.
January 1992, Acta neurologica Scandinavica. Supplementum,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain.
June 2001, Journal of chemical neuroanatomy,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease.
July 1999, Neuroscience letters,
I Tooyama, and T Kawamata, and D Walker, and T Yamada, and K Hanai, and H Kimura, and M Iwane, and K Igarashi, and E G McGeer, and P L McGeer
Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson's disease.
January 2018, NPJ Parkinson's disease,
Copied contents to your clipboard!